1. Home
  2. LTBR vs KALV Comparison

LTBR vs KALV Comparison

Compare LTBR & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$14.99

Market Cap

575.6M

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.12

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTBR
KALV
Founded
1992
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
575.6M
551.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LTBR
KALV
Price
$14.99
$16.12
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.00
AVG Volume (30 Days)
1.0M
1.3M
Earning Date
02-25-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,426,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$204.16
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.10
$8.67
52 Week High
$31.34
$19.00

Technical Indicators

Market Signals
Indicator
LTBR
KALV
Relative Strength Index (RSI) 42.86 54.89
Support Level $15.84 $15.22
Resistance Level $18.12 $16.16
Average True Range (ATR) 1.49 0.88
MACD -0.21 -0.01
Stochastic Oscillator 8.24 76.95

Price Performance

Historical Comparison
LTBR
KALV

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: